CoChat

Changes in markers of liver function in relation to changes in perfluoroalkyl substances - A longitudinal study

Salihovic, Samira, Stubleski, Jordan, Kärrman, Anna, Larsson, Anders, Fall, Tove, Lind, Lars, Lind, P. Monica · 2018 · Environment International
Cited by 130

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND While it is known that perfluoroalkyl substances (PFASs) induce liver toxicity in experimental studies, the evidence of an association in humans is inconsistent. OBJECTIVE The main aim of the present study was to examine the association of PFAS concentrations and markers of liver function using panel data. METHODS We investigated 1002 individuals from Sweden (50% women) at ages 70, 75 and 80 in 2001-2014. Eight PFASs were measured in plasma using isotope dilution ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS). Bilirubin and hepatic enzymes alanine aminotransferase (ALT), alkaline phosphatase (ALP), and γ-glutamyltransferase (GGT) were determined in serum using an immunoassay methodology. Mixed-effects linear regression models were used to examine the relationship between the changes in markers of liver function and changes in PFAS levels. RESULTS The changes in majority of PFAS concentrations were positively associated with the changes in activity of ALT, ALP, and GGT and inversely associated with the changes in circulating bilirubin after adjustment for gender and the time-updated covariates LDL- and HDL-cholesterol, serum triglycerides, BMI, statin use, smoking, fasting glucose levels and correction for multiple testing. For example, changes in perfluorononanoic acid (PFNA) were associated with the changes liver function markers βBILIRUBIN = -1.56, 95% confidence interval (CI) -1.93 to -1.19, βALT = 0.04, 95% CI 0.03-0.06, and βALP = 0.11, 95% CI 0.06-0.15. CONCLUSION Our longitudinal assessment established associations between changes in markers of liver function and changes in plasma PFAS concentrations. These findings suggest a relationship between low-dose background PFAS exposure and altered liver function in the general population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.envint.2018.04.052

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Azzalini, 2010, Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats, Hepatology, 51, 10.1002/hep.23516 · DOI · Paper page
  2. Beggs, 2016, The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction, Toxicol. Appl. Pharmacol., 304, 10.1016/j.taap.2016.05.001 · DOI · Paper page
  3. Bjork, 2011, Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes, Toxicology, 288, 10.1016/j.tox.2011.06.012 · DOI · Paper page
  4. Bohnen, 1991, Influence of age and sex on 19 blood variables in healthy subjects, Z. Gerontol., 24
  5. Butenhoff, 2002, Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months, Toxicol. Sci., 69, 10.1093/toxsci/69.1.244 · DOI · Paper page
  6. Carlsson, 2010, Reference values for 27 clinical chemistry tests in 70-year-old males and females, Gerontology, 56, 10.1159/000251722 · DOI
  7. Darrow, 2016, Modeled perfluorooctanoic acid (PFOA) exposure and liver function in a mid-Ohio Valley community, Environ. Health Perspect., 124, 10.1289/ehp.1510391 · DOI · Paper page
  8. Emmett, 2006, Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters, J. Occup. Environ. Med., 48, 771, 10.1097/01.jom.0000233380.13087.37 · DOI · Paper page
  9. Eriksen, 2010, Genotoxic potential of the perfluorinated chemicals PFOA, PFOS, PFBS, PFNA and PFHxA in human HepG2 cells, Mutat. Res. Genet. Toxicol. Environ. Mutagen., 700, 10.1016/j.mrgentox.2010.04.024 · DOI · Paper page
  10. Gallo, 2012, Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure, Environ. Health Perspect., 120, 10.1289/ehp.1104436 · DOI · Paper page
  11. Gilliland, 1996, Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men, Am. J. Ind. Med., 29, 560, 10.1002/(SICI)1097-0274(199605)29:5<560::AID-AJIM17>3.0.CO;2-Z · DOI · Paper page
  12. Gleason, 2015, Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007–2010, Environ. Res., 136, 10.1016/j.envres.2014.10.004 · DOI · Paper page
  13. Inoguchi, 2007, Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes, JAMA, 298, 10.1001/jama.298.12.1398-b · DOI
  14. Kärrman, 2010, Biomonitoring perfluorinated compounds in Catalonia, Spain: concentrations and trends in human liver and milk samples, Environ. Sci. Pollut. Res., 17, 10.1007/s11356-009-0178-5 · DOI · Paper page
  15. Kudo, 2006, Responses of the liver to perfluorinated fatty acids with different carbon chain length in male and female mice:in relation to induction of hepatomegaly, peroxisomal beta-oxidation and microsomal 1-acylglycerophosphocholine acyltransferase, Biol. Pharm. Bull., 29, 10.1248/bpb.29.1952 · DOI · Paper page
  16. Lin, 2006, Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study, Circulation, 114, 10.1161/CIRCULATIONAHA.106.633206 · DOI · Paper page
  17. Lin, 2010, Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults, Am. J. Gastroenterol., 105
  18. Lind, 2005, A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study, Arterioscler. Thromb. Vasc. Biol., 25, 10.1161/01.ATV.0000184769.22061.da · DOI · Paper page
  19. Lind, 2017, Circulating levels of perfluoroalkyl substances (PFASs) and carotid artery atherosclerosis, Environ. Res., 152, 10.1016/j.envres.2016.10.002 · DOI · Paper page
  20. Mayer, 2000, Association of serum bilirubin concentration with risk of coronary artery disease, Clin. Chem., 46
  21. Mundt, 2007, Clinical epidemiological study of employees exposed to surfactant blend containing perfluorononanoic acid, Occup. Environ. Med., 64, 10.1136/oem.2007.032664 · DOI
  22. Olsen, 2007, Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers, Int. Arch. Occup. Environ. Health, 81, 10.1007/s00420-007-0213-0 · DOI · Paper page
  23. Olsen, 2000, Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers, Drug Chem. Toxicol., 23, 603, 10.1081/DCT-100101973 · DOI · Paper page
  24. Olsen, 2012, Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities, J. Occup. Environ. Med., 54, 10.1097/JOM.0b013e31825461d2 · DOI · Paper page
  25. Rosen, 2008, Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPARα and CAR, Toxicol. Sci., 103, 10.1093/toxsci/kfn025 · DOI · Paper page
  26. Rosen, 2017, PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling, Toxicology, 387, 10.1016/j.tox.2017.05.013 · DOI · Paper page
  27. Rosenmai, 2018, Relationship between peroxisome proliferator-activated receptor alpha activity and cellular concentration of 14 perfluoroalkyl substances in HepG2 cells, J. Appl. Toxicol., 38, 219, 10.1002/jat.3515 · DOI · Paper page
  28. Sakr, 2007, Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers, J. Occup. Environ. Med., 49, 1086, 10.1097/JOM.0b013e318156eca3 · DOI · Paper page
  29. Sakr, 2007, Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate, J. Occup. Environ. Med., 49
  30. Salihovic, 2013, A rapid method for the determination of perfluoroalkyl substances including structural isomers of perfluorooctane sulfonic acid in human serum using 96-well plates and column-switching ultra-high performance liquid chromatography tandem mass spectrometry, J. Chromatogr. A, 1305, 164, 10.1016/j.chroma.2013.07.026 · DOI
  31. Salihovic, 2015, Perfluoroalkyl substances (PFAS) including structural PFOS isomers in plasma from elderly men and women from Sweden: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS), Environ. Int., 82, 10.1016/j.envint.2015.05.003 · DOI
  32. Schmucker, 2005, Age-related changes in liver structure and function: implications for disease?, Exp. Gerontol., 40, 10.1016/j.exger.2005.06.009 · DOI · Paper page
  33. Shankar, 2012, Perfluorooctanoic acid and cardiovascular disease in US adults, Arch. Intern. Med., 172, 10.1001/archinternmed.2012.3393 · DOI · Paper page
  34. Steenland, 2010, Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA), Environ. Health Perspect., 118, 10.1289/ehp.0901827 · DOI · Paper page
  35. Stocker, 1987, Bilirubin is an antioxidant of possible physiological importance, Science, 235, 10.1126/science.3029864 · DOI · Paper page
  36. Stubleski, 2016, Changes in serum levels of perfluoroalkyl substances during a 10-year follow-up period in a large population-based cohort, Environ. Int., 95, 10.1016/j.envint.2016.08.002 · DOI
  37. Sun, 2018, Plasma concentrations of perfluoroalkyl substances and risk of type 2 diabetes: a prospective investigation among U.S. women, Environ. Health Perspect., 126, 10.1289/EHP2619 · DOI · Paper page
  38. Tietz, 1992, Laboratory values in fit aging individuals—sexagenarians through centenarians, Clin. Chem., 38
  39. Tilton, 2008, Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout, Environ. Health Perspect., 116, 10.1289/ehp.11190 · DOI · Paper page
  40. Vanden Heuvel, 2006, Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-α, -β, and -γ, liver X receptor-β, and retinoid X receptor-α, Toxicol. Sci., 92, 10.1093/toxsci/kfl014 · DOI · Paper page
  41. Vı́tek, 2002, Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels, Atherosclerosis, 160, 10.1016/S0021-9150(01)00601-3 · DOI · Paper page
  42. Wolf, 2012, Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARα) by perfluoroalkyl acids (PFAAs): further investigation of C4–C12 compounds, Reprod. Toxicol., 33, 10.1016/j.reprotox.2011.09.009 · DOI · Paper page
  43. Yamada, 2006, Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome, Atherosclerosis, 189, 10.1016/j.atherosclerosis.2005.11.036 · DOI · Paper page
  44. Yamaguchi, 2013, Consumption of seafood, serum liver enzymes, and blood levels of PFOS and PFOA in the Japanese population, J. Occup. Health, 55, 10.1539/joh.12-0264-OA · DOI · Paper page
  45. Yamamoto, 2015, Perfluorooctanoic acid binds to peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation in 3T3-L1 adipocytes, Biosci. Biotechnol. Biochem., 79, 10.1080/09168451.2014.991683 · DOI · Paper page

Cited by

See all 130

Metadata

Authors
Salihovic, S., Stubleski, J., Kärrman, A., Larsson, A., Fall, T., Lind, L., & Lind, P. M.
Venue
Environment International
Publisher
Elsevier BV
Published
2018-08
Volume
117
Pages
196-203
ISSN
0160-4120 (ISSN-L)
OpenAlex
W2800179100
Cited by
130
References
8
FWCI
3.69
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Svenska Forskningsrådet Formas (2013-478, 2015-756, 2007-2047)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.